Acrivon Therapeutics, Inc. (ACRV) Key Metrics
ACRV valuation today
Trailing 12 months · as of October 17, 2026- Market cap
- $70.3M
- Enterprise value
- $433,925
- P/E (TTM)
- —
- Forward P/E
- —
- PEG ratio
- —
- Price / sales
- —
- Price / book
- 1.0 10-yr median 1.1
- EV / EBITDA
- —
- Dividend yield
- —
- Beta
- 1.93
ACRV key metrics, 2020–2025
Fiscal year ended December 31, 2025 · U.S. dollarsACRV valuation Price multiples at each fiscal year-end price.
ACRV returns How much profit the business earns on the capital it uses.
ACRV per-share figures Results divided by the shares outstanding at year-end.
ACRV financial health Debt, liquidity and how easily interest is covered.
ACRV efficiency & capital use Working capital cycle and where the cash goes.
ACRV valuation history
ACRV returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
ACRV debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
ACRV price vs earnings per share
ACRV key metrics
2020–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|---|
| Valuation | ||||||
| Market capitalization | $92.8M | $230.5M | $108.6M | $252.5M | — | — |
| Enterprise value | −$23.1M | $54.7M | −$14.2M | $129.7M | — | — |
| Price / book | 0.8 | 1.3 | 0.9 | 1.5 | — | — |
| Earnings yield | −83.9% | −34.9% | −55.6% | −11.8% | — | — |
| Free cash flow yield | −70.4% | −29.7% | −40.4% | −12.8% | — | — |
| Shareholder yield (dividends + buybacks) | — | — | — | 0.0% | — | — |
| Share price at fiscal year-end | $2.41 | $6.02 | $4.92 | $11.52 | — | — |
| Per share | ||||||
| Revenue per share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Earnings per share | −$2.02 | −$2.10 | −$2.74 | −$1.35 | −$1.26 | −$0.41 |
| Operating cash flow per share | −$1.65 | −$1.71 | −$1.93 | −$1.37 | −$1.08 | −$0.22 |
| Free cash flow per share | −$1.70 | −$1.79 | −$1.99 | −$1.47 | −$1.10 | −$0.22 |
| Cash per share | $3.08 | $4.69 | $5.77 | $5.83 | $7.72 | $0.12 |
| Book value per share | $2.92 | $4.62 | $5.49 | $7.78 | −$1.84 | −$0.65 |
| Tangible book value per share | $2.92 | $4.62 | $5.49 | $7.78 | −$1.84 | −$0.65 |
| Capex per share | $0.04 | $0.07 | $0.06 | $0.10 | $0.02 | $0.00 |
| Debt per share | $0.07 | $0.10 | $0.21 | $0.23 | $0.44 | $0.00 |
| Shares outstanding | 38.5M | 38.3M | 22.1M | 21.9M | 12.9M | 12.9M |
| Change in shares outstanding | +0.6% | +73.5% | +0.7% | +69.8% | 0.0% | — |
| Returns & profitability | ||||||
| Return on equity (ROE) | −53.9% | −54.1% | −41.4% | −40.5% | — | — |
| Return on assets (ROA) | −47.7% | −48.1% | −37.8% | −20.6% | −29.9% | −242.8% |
| Return on tangible assets | −60.1% | −41.0% | −43.7% | −16.4% | −15.2% | −242.8% |
| Financial health | ||||||
| Total debt | $2.7M | $3.6M | $4.6M | $5.0M | $5.6M | $58,000 |
| Cash & short-term investments | $118.6M | $179.5M | $127.5M | $127.8M | $99.6M | $1.6M |
| Net debt | −$115.9M | −$175.8M | −$122.8M | −$122.8M | −$94.0M | −$1.5M |
| Debt / equity | 0.02 | 0.02 | 0.04 | 0.03 | — | — |
| Debt / assets | 0.02 | 0.02 | 0.03 | 0.03 | 0.05 | 0.03 |
| Current ratio | 7.69 | 10.55 | 9.75 | 20.27 | 34.46 | 2.80 |
| Quick ratio | 7.69 | 10.55 | 9.75 | 20.27 | 34.46 | 2.80 |
| Interest coverage | — | — | — | -21.9 | -274.3 | — |
| Working capital | $104.8M | $164.4M | $116.4M | $125.6M | $97.5M | $1.1M |
| Invested capital | −$3.4M | $951,000 | −$1.6M | $47.7M | −$117.8M | −$9.9M |
| Tangible asset value | $112.5M | $176.8M | $121.2M | $170.5M | −$23.8M | −$8.4M |
| Net current asset value | $103.2M | $161.8M | $112.6M | $121.3M | −$30.0M | −$8.9M |
| Graham net-net per share | $2.63 | $4.17 | $5.00 | $5.34 | −$2.39 | −$0.70 |
| Capital allocation | ||||||
| Share buybacks (net) | — | — | — | $0 | — | — |
| Capex / depreciation | 1.23 | 2.75 | 2.40 | 5.95 | 6.43 | 1.15 |
| Efficiency | ||||||
| Days payables outstanding | 408.5 | 1,053.3 | 2,026.6 | 311.3 | 241.3 | 3,818.5 |
| Payables turnover | 0.89 | 0.35 | 0.18 | 1.17 | 1.51 | 0.10 |
| Asset turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Average payables | $1.5M | $2.9M | $3.0M | $934,000 | $550,000 | $136,000 |
| Intangibles / total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Computed from ACRV's annual financial statements (latest annual report filed March 19, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
ACRV valuation and financial ratios
Acrivon Therapeutics earned a return on equity of −53.9% in fiscal 2025. It ended the year with $2.7 million of debt and $118.6 million in cash and short-term investments, a net cash position of $115.9 million. The share count rose 198.3% from 12.9M to 38.5M over 5 years.
See the ACRV income statement, the ACRV chart for price history, or the ACRV stock overview for the latest quote and news.
ACRV key metrics FAQ
What is Acrivon Therapeutics's return on equity?
Acrivon Therapeutics's return on equity (ROE) was −53.9% in fiscal 2025: net income of -$77.9 million on average shareholders' equity of $144.7 million.
How much debt does Acrivon Therapeutics have?
Acrivon Therapeutics had total debt of $2.7 million at the end of fiscal 2025, a debt-to-equity ratio of 0.02 and more cash than debt.
What is Acrivon Therapeutics's free cash flow yield?
Acrivon Therapeutics generated -$65.3 million of free cash flow in fiscal 2025, a free cash flow yield of −70.4% on its market value at year-end ($92.8 million).
What is Acrivon Therapeutics's current ratio?
Acrivon Therapeutics's current ratio was 7.69 at the end of fiscal 2025: current assets were 7.69 times current liabilities.